Enríquez VME, Bobadilla FNO, Rodríguez JÓA, Guerra MÁ, Carrasco NL, Varela SJ

Language: Spanish
References: 13
Page: 51-56
PDF size: 176.20 Kb.

ABSTRACT

Objective: To assess the efficiency of platelet rich plasma in treating chronic non-healing ischemic diabetic ulcers.
Material and methods: A prospective study was conducted. We included 24 diabetic patients (13 men and 11 women) with ischemic ulcers not amenable to revascularization, with ages ranging from 30 to 85 years old. A single doses of 20-30 mL autologous platelet rich plasma was infiltrated around the lesion, the follow up was every 2 weeks and the outcome was reviewed 8 weeks post-treatment, a difference was established between the pretreatment ulcer area in mm² and the final ulcer area at 8 weeks posttreatment. The treatment was considered efficient if the p value was ‹ 0.05 using statistical methods no-parametric (Wilcoxon Rank Test) calculated with 99% of confidence. The data collected was analyzed in Software Package for Social Sciences, SPSS, Inc., NC, EUA, 2006, version 15.0.
Results:After 8 weeks of follow up, the ulcers showed improvement in 79.2% (n = 19) (p = 0.000) with healing in › 70% of the diameter of the ulcers, in the remaining 20.8% (n = 5) there was no reduction in the size of the ulcer and mayor amputation of the limb was required before the end of the treatment.
Conclusion: Platelet growth factor content in the platelet rich plasma is an innocuous autologous therapy. In our short experience, it has proved useful in the management of diabetic foot ulcers not amenable to revascularization, with an efficiency of 79.2%.

REFERENCES

1. Logerfo WF. Tratamiento de las úlceras del pie en la diabetes mellitus. En: Rutherford (eds.). Cirugía vascular. 2nd. ed. Barcelona: Elsevier; 2006, p. 1256-60.

2. Lavery LA, Amstrong DG, Wunderlich RP, Trewell J, Boulton AJ. Diabetic foot syndrome: Evaluating the prevalence and incidence pathology in Mexican Americans and non Hispanic whites from ulcers stratified by etiology. Diabetes Care 2003; 26(5): 1435-8.

3. LoGerfo FW. Trends in the care of the diabetic: Expanded role of arterial reconstruction. Arch Surg 1992; 127: 617-21.

4. Knighton DR, Ciresi K, Fiegel VD, Schumerth S, Butler E, Cerra F. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived healing formula. Surg Gynecol Obstet 1990; 170(1): 56-60.

5. Ferrara N, Davis-Smyth T. The biology of vascular endotelial growth factor. Endocr Rev 1997; 18(1): 4-25.

6. Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB. Induction of vascular endothelial growth factor by insulin- like growth 1 in colorectal carcinoma. J Biol Chem 1996; 271: 29483-88.

7. Rasmussen HS. Angiogenic gene therapy strategies for the treatment of cardiovascular disease. Curr Opin Mol Ther 2002; 4: 476-81.

8. Takeshita S, Zheng LP, Brogi E. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Invest 1994; 93: 662-70.

9. Hamano K, Nishida M. Hirata K. Local implantation of autologus Bone marrow cells for therapeutic angiogenesis in patient with ischemic heart disease: clinical trial and preliminary results. Jpn Circ J 2001; 65: 845-7.

10. Caramelo C, Castilla FR. González-Pacheco O, Martín M. Papel del factor de crecimiento vascular (VEGF) en la respuesta proliferativa endotelial. Nefrología 2005; 18(1): 2337.

11. Paolini JE, Lamelza V, Cohen C, Giraldez N, Rabuffetti M. Parche plaquetario autólogo. Utilización en úlceras crónicas. Forum de flebología y linfología 2006; 8(1): 006. Disponible en: http://www.circulacionforum.com.ar/ Forum/vol8n1.html

12. Wieman T; Beclarpermin Gel Studies Group. Clinical efficacy of Beclapermin (rh PDGF-BB) gel. Am SJ Surg 1998; 176: 745-95.

13. Castro G, Liceaga G, Arrioja A, Calleja JM, Espejel A. Guía Clínica basada en evidencia para el manejo del paciente diabético. Med Int Mex 2009; 25(6): 481-526.